A panel of FDA advisers endorsed the approval of rivaroxaban, an anti-coagulant by Johnson & Johnson and Bayer Healthcare Pharmaceuticals, as a preventive treatment for deep-vein thrombosis and pulmonary embolism in patients undergoing total knee- or hip-replacement surgery. The product could become an alternative to blockbuster drug warfarin if it gains final FDA clearance.

Full Story:

Related Summaries